



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:
22.05.2019 Bulletin 2019/21

(45) Date of publication and mention
of the grant of the patent:
20.03.2019 Bulletin 2019/12

(21) Application number: **12812432.8**

(22) Date of filing: **30.11.2012**

(51) Int Cl.:
C12N 15/113^(2010.01) A61K 31/7125^(2006.01)
A61P 25/00^(2006.01)

(86) International application number:
PCT/US2012/067475

(87) International publication number:
WO 2013/082551 (06.06.2013 Gazette 2013/23)

(54) **INDUCED EXON INCLUSION IN SPINAL MUSCLE ATROPHY**
INDUZIERTE EXON-INKLUSION IN SPINALER MUSKELATROPHIE
INCLUSION D'EXON INDUITE POUR L'AMYOTROPHIE SPINALE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(30) Priority: **30.11.2011 US 201161565499 P**

(43) Date of publication of application:
08.10.2014 Bulletin 2014/41

(73) Proprietor: **Sarepta Therapeutics, Inc.**
Cambridge, MA 02142 (US)

(72) Inventors:
• **LINSLEY, Peter**
Seattle, WA 98119 (US)
• **LEPPERT, Brian, James**
Kenmore, WA 98028 (US)

(74) Representative: **D Young & Co LLP**
Briton House
Briton Street
Southampton SO14 3EB (GB)

(56) References cited:
WO-A1-2010/120820 WO-A2-2007/002390
WO-A2-2008/036127 WO-A2-2011/150408

US-A1- 2006 287 268 US-A1- 2008 194 463
US-A1- 2011 269 820

- **A. H. M. BURGHESE ET AL: 'Antisense oligonucleotides and spinal muscular atrophy: skipping along' GENES & DEVELOPMENT vol. 24, no. 15, 01 August 2010, pages 1574 - 1579, XP55044388 DOI: 10.1101/gad.1961710 ISSN: 0890-9369**
- **CARTEGNI L ET AL: "Correction of disease-associated exon skipping by synthetic exon-specific activators", NATURE STRUCTURAL BIOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 10, no. 2, 1 February 2003 (2003-02-01), pages 120-125, XP002262731, ISSN: 1072-8368, DOI: 10.1038/NSB887**
- **N. N. SINGH ET AL: "An antisense microwalk reveals critical role of an intronic position linked to a unique long-distance interaction in pre-mRNA splicing", RNA, vol. 16, no. 6, 1 June 2010 (2010-06-01), pages 1167-1181, XP55056239, ISSN: 1355-8382, DOI: 10.1261/rna.2154310**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- HUA YIMIN ET AL: "Enhancement of SMN2 exon 7 inclusion by antisense oligonucleotides targeting the exon", PLOS BIOLOGY, PUBLIC LIBRARY OF SCIENCE, US, vol. 5, no. 4, 1 April 2007 (2007-04-01), page E73, XP002596113, ISSN: 1544-9173
- LIM S R ET AL: "Modulation of Survival Motor Neuron Pre-mRNA Splicing by Inhibition of Alternative 3'Splice Site Pairing", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 276, no. 48, 30 November 2001 (2001-11-30), pages 45476-45483, XP008124558, ISSN: 0021-9258, DOI: 10.1074/JBC.M107632200 [retrieved on 2001-10-02]
- D. L. SWENSON ET AL: "Chemical Modifications of Antisense Morpholino Oligomers Enhance Their Efficacy against Ebola Virus Infection", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 53, no. 5, 1 May 2009 (2009-05-01), pages 2089-2099, XP55056348, ISSN: 0066-4804, DOI: 10.1128/AAC.00936-08
- SAZANI P ET AL: "Nuclear antisense effects of neutral, anionic and cationic oligonucleotide analogs", NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 29, no. 19, 1 October 2001 (2001-10-01), pages 3965-3974, XP002978135, ISSN: 0305-1048